- Home
- DRMA vs EPWK Comparison
DRMA vs EPWK Comparison
Compare DRMA & EPWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- EPWK
- Stock Information
- Founded
- DRMA 2014
- EPWK 2011
- Country
- DRMA United States
- EPWK China
- Employees
- DRMA N/A
- EPWK N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- EPWK
- Sector
- DRMA Health Care
- EPWK
- Exchange
- DRMA Nasdaq
- EPWK Nasdaq
- Market Cap
- DRMA 2.1M
- EPWK 2.3M
- IPO Year
- DRMA 2021
- EPWK 2025
- Fundamental
- Price
- DRMA $3.11
- EPWK $0.06
- Analyst Decision
- DRMA Strong Buy
- EPWK
- Analyst Count
- DRMA 1
- EPWK 0
- Target Price
- DRMA $10.00
- EPWK N/A
- AVG Volume (30 Days)
- DRMA 51.3K
- EPWK 111.4M
- Earning Date
- DRMA 11-07-2025
- EPWK 10-24-2025
- Dividend Yield
- DRMA N/A
- EPWK N/A
- EPS Growth
- DRMA N/A
- EPWK N/A
- EPS
- DRMA N/A
- EPWK N/A
- Revenue
- DRMA N/A
- EPWK $20,164,008.00
- Revenue This Year
- DRMA N/A
- EPWK N/A
- Revenue Next Year
- DRMA N/A
- EPWK N/A
- P/E Ratio
- DRMA N/A
- EPWK N/A
- Revenue Growth
- DRMA N/A
- EPWK 10.25
- 52 Week Low
- DRMA $2.90
- EPWK $0.06
- 52 Week High
- DRMA $23.70
- EPWK $26.00
- Technical
- Relative Strength Index (RSI)
- DRMA 32.99
- EPWK 31.38
- Support Level
- DRMA $2.95
- EPWK $0.07
- Resistance Level
- DRMA $3.32
- EPWK $0.08
- Average True Range (ATR)
- DRMA 0.24
- EPWK 0.01
- MACD
- DRMA -0.01
- EPWK 0.01
- Stochastic Oscillator
- DRMA 16.42
- EPWK 4.49
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About EPWK EPWK Holdings Ltd. Class A Ordinary Shares
EPWK Holdings Ltd create an innovative and efficient crowdsourcing platform to connect businesses with great talents. It operates online marketplace to enable businesses (buyers) and service providers (sellers) to find each other. The platform users consist of buyers who seek talents for their jobs and sellers who offer different talents and skills. The company derives revenue mainly comes from providing various value-added services for users on both supply and demand sides.